Straits Times Index
3,218.72 +27.56 (+0.86%) Nikkei
26,653.34 +106.29 (+0.40%) Hang Seng
20,277.05 +326.84 (+1.64%) FTSE 100
7,464.80 +46.65 (+0.63%) BTC-USD
29,982.94 -774.53 (-2.52%) CMC Crypto 200
672.02 +429.34 (+176.92%)
Roche Holding AG (RHHBF)
| Previous close | 349.50 |
| Open | 341.00 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 341.00 - 353.00 |
| 52-week range | 341.00 - 473.65 |
| Volume | |
| Avg. volume | 768 |
| Market cap | 279.263B |
| Beta (5Y monthly) | 0.31 |
| PE ratio (TTM) | 21.87 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 9.97 (2.85%) |
| Ex-dividend date | 17 Mar 2022 |
| 1y target est | N/A |
- Business Wire
Genentech Reports Interim Results for Phase III SKYSCRAPER-01 Study in PD-L1-High Metastatic Non-Small Cell Lung Cancer
SOUTH SAN FRANCISCO, Calif., May 11, 2022--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced results from its Phase III SKYSCRAPER-01 study, evaluating the investigational anti-TIGIT immunotherapy tiragolumab plus Tecentriq® (atezolizumab) versus Tecentriq alone as an initial (first-line) treatment for people with PD-L1-high locally advanced or metastatic non-small cell lung cancer (NSCLC). The study did not meet its co-primary endpoint of progression-free surv
- Business Wire
New Three-Year Data for Genentech’s Evrysdi (risdiplam) Show Long-Term Improvements in Survival and Motor Milestones in Babies With Type 1 Spinal Muscular Atrophy (SMA)
SOUTH SAN FRANCISCO, Calif., April 29, 2022--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced new three-year data from the FIREFISH study, including one-year data from the open label extension, reinforcing the long-term efficacy and safety of Evrysdi® (risdiplam) in infants with symptomatic Type 1 spinal muscular atrophy (SMA). The data showed an estimated 91% of infants (n=58) treated with Evrysdi were alive after three years of treatment. The Evrysdi-treated
- Business Wire
New Data for Genentech’s Ocrevus (ocrelizumab) Show Benefit in Disability Progression and Cognitive Decline in Both Secondary Progressive and Primary Progressive Multiple Sclerosis
SOUTH SAN FRANCISCO, Calif., April 04, 2022--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced new Ocrevus® (ocrelizumab) data that show its benefit on disease progression and cognitive outcomes in primary progressive multiple sclerosis (PPMS) and secondary progressive MS (SPMS). Separate analyses on treatment disparities among newly diagnosed patients with MS by race and ethnicity will be a platform presentation at the 74th American Academy of Neurology (AAN)
